FEATURED EDITORIAL
The ability to precisely control the activity of NMDA receptors could play a role in the treatment of a range of neurodevelopmental disorders. We caught up with GRIN Therapeutics' chief medical officer to discuss drug development.
- AI Plus The Scientific Method Might Reinvent Drug Discovery
- Developing Interleukin-2 For Cell Therapies: Key Considerations
- Unlocking The Pharmacological Potential Of Antibodies
- Weight Of Evidence Assessments For Carcinogenicity Studies: An Overview
- Advancing CAR T Cell Therapy with Logic Gate Engineering
- Oligos Step Into The Spotlight: A Growing Force In Genetic Medicine
- From Concept To Confidence: A Collaborative Path To Validating NAMs
FEATURED APPLICATION CONTENT
-
Characterizing the PROTAC hook effect is crucial for selecting candidates with enhanced cooperativity. Gain confidence with flexible, in-solution affinity measurements that reveal key biophysical parameters and align with established three-component binding models.
-
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Explore how process intensification can revolutionize monoclonal antibody manufacturing to boost productivity, cut costs, and enhance sustainability with scalable strategies and real-world results.
-
See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.
-
As regulations tighten, biomanufacturers are adopting single-use tech to boost compliance, reduce labor, and streamline fill-finish operations from the ground up.
-
Learn how researchers optimized CHO cell culture to boost IgG1 titer to 5.8 g/L and improve viability, which cut development time from 14 days to 12 while enhancing productivity.
-
Learn how a comprehensive, variant-aware screening workflow for therapeutic gene editing can identify and nominate the most favorable guide RNAs for clinical development.
-
Optimizing input parameters like DBC, flow rate, and resin durability is key to boosting productivity in downstream bioprocessing. Discover how to tailor resin choices to meet your specific process requirements.
-
Accelerate drug discovery by leveraging transiently transfected assay-ready cells. This method improves assay sensitivity and reduces variability for GPCRs.
-
Learn about a novel cell-based assay that can advance ubiquitin ligase drug discovery. This high-throughput method simplifies assay development, saving time and resources.
-
High-throughput screening of KCNQ2 ion channel variants provides insights into epilepsy and treatment responses. This validated method supports rapid characterization for precision medicine.
-
Navigate the FDA's gene therapy guidelines with advanced risk assessment strategies. Optimize gene editing and ensure regulatory alignment for safer, more effective therapies.
FEATURED NEWS HEADLINES
- Elsevier Launches PharmaPendium AI, Designed To Support Faster And More Reliable Access To Regulatory Insights For Drug Development
- Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development
- Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-103, A Potential Best-In-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
- Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers For Improved Conditioning And Certain Autoimmune Diseases
- BON Announces Identification Of Promising Weight-Managing Compounds From Tea via AI-Powered New Drug R&D Platform
- Quotient Sciences And CPI To Accelerate RNA Drug Development With Joint Venture
- Norma Completes Quantum AI Algorithm Validation On NVIDIA
- Promising New Drug For People With Stubborn High Blood Pressure
- Piramal Pharma Solutions Supports George Medicines In Developing Its New Drug For Hypertension, WIDAPLIK™ (telmisartan, amlodipine And indapamide)
- Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation For VGT-1849B, A Novel And Selective Candidate For The Treatment Of Polycythemia Vera
ARCHIVED NEWSLETTER
- 09.04.25 -- Learn how to enhance productivity in your monoclonal antibody (mAb) capture process
- 09.02.25 -- From Undruggable To Druggable: The Science Reshaping Small Molecule Discovery
- 08.28.25 -- Find Small Molecule CDMOs With Available Capacity
- 08.27.25 -- Learn From Cell & Gene Therapy CDMOs With Available Capacity
- 08.26.25 -- Multi-Indication Strategies Reshape Immunology's R&D Strategy